- HK$52.02bn
- HK$171.29bn
- CNY575.17bn
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For
Brief: Sinopharm Says China National Accord Medicines H1 Net Profit Attributable RMB 606.2 Million
Brief: Sinopharm Establishes Strategic Partnership With Pfizer
Brief: Blackrock's Long Position In H Shares Of Sinopharm Group Increases To 9.86% On June 5 From 8.84%, Says HKEX
Brief: Blackrock's Long Position In H-Shares Of Sinopharm Group Increases To 9.84% On June 3 - HKEX
Sinopharm Group touches 6-month low as quarterly profit slips
Brief: Sinopharm Group Posts Qtrly Total Operating Revenue RMB 140.77 Billion
Brief: Sinopharm Group Says QTRLY Net Profit Attributable For Sinopharm Accord RMB287.5 Million
Brief: Sinopharm Group Posts FY Profit Attributable Of RMB7.16 BLN
Brief: Sinopharm Says Zhao Bingxiang Resigns As Chairman
Brief: JPMorgan Chase & Co's Short Position In H-Shares Of Sinopharm Group Decreased To 1.45% On Nov 21 - HKEX
Factbox: Corporate concerns mount ahead of Trump and Xi talks in South Korea
Brief: Sinopharm Group Posts 9M Net Profit Attributable RMB5.31 Billion
Brief: Sinopharm Group Says HY Net Profit Attributable For China National Medicines Corp Of RMB948.5 Million
Brief: Sinopharm Group Appoints Hu Ligang As A Vice President
China's Sinopharm rises most in over six months as quarterly profit climbs